Healthcare Industry News: hereditary angioedema
News Release - May 24, 2006
Dyax Announces the Appointment of Peggy Berry as Senior Vice President of Quality and Regulatory AffairsCAMBRIDGE, Mass.--(HSMN NewsFeed)--May 24, 2006--Dyax Corp. (Nasdaq:DYAX ) today announced that Peggy Berry has joined the Company as Senior Vice President, Quality and Regulatory Affairs. Ms. Berry joins Dyax's senior management team where she will be responsible for overseeing the Company's quality and regulatory departments.
Ms. Berry is a seasoned professional, with over 20 years of experience. She started her career at the Food and Drug Administration (FDA) in the Center for Drug Evaluation and Research division, where she participated in the review and approval of New Drug Applications (NDA), served as a liaison between Drug Evaluation and the Office of Compliance, and wrote policy and procedure documents. Subsequently, she spent her time primarily in corporate Regulatory Affairs at Cato Research, Ilex Oncology, Dey LP, and AstraZeneca. In her years of corporate experience, she obtained approval for four NDA products and two Abbreviated New Drug Application products and contributed to the successful execution of many additional development programs.
Dr. Thomas Beck, President and Chief Operating Officer of Dyax stated, "I am delighted to have Ms. Berry join the Dyax team. She has extensive regulatory experience, which will aid in the continuing regulatory dialog with the FDA. Ms. Berry will be responsible for moving DX-88 in hereditary angioedema through the regulatory process as well as Dyax's other opportunities, including DX-88 in on-pump CABG surgery, DX-2240 for cancer indications and for other products in the emerging Dyax portfolio."
Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on cancer and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.
Dyax's lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. In its joint venture with Genzyme Corporation, Dyax has successfully completed three Phase II trials of DX-88 for the treatment of hereditary angioedema (HAE). A Phase III trial is ongoing. Independently, Dyax has successfully completed a Phase I/II trial of DX-88 for the prevention of blood loss during heart surgery (CABG procedures) and is planning a Phase IIb trial while it continues partnering discussions for further development of DX-88 in this indication. DX-88 has orphan drug designation in the U.S. and E.U. for the treatment of angioedema, as well as Fast Track designation in the U.S.
Dyax identified DX-88 and other compounds in its pipeline using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 75 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.
This press release contains forward-looking statements regarding Dyax Corp., including statements regarding the ongoing development of DX-88 and DX-2240. Statements that are not historical facts are based on Dyax's current expectations, beliefs, assumptions, estimates, forecasts and projections for Dyax and the industry and markets in which Dyax competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements because of uncertainties associated with various activities and aspects of Dyax's business, including the timing and results of clinical trials, regulatory review of Dyax's products, and other risk factors described or referred to in Dyax's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligation to update or revise these statements, except as may be required by law.
Dyax and the Dyax logo are the registered trademarks of Dyax Corp.
Dyax is headquartered in Cambridge, Massachusetts, and has antibody discovery facilities in Liege, Belgium. For online information about Dyax, please visit www.dyax.com.
Source: Dyax Corp
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.